## Mona L Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4066238/publications.pdf

Version: 2024-02-01

759233 839539 1,871 18 12 18 h-index citations g-index papers 18 18 18 2254 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRÓ) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2—Assessing Respondent Understanding. Value in Health, 2011, 14, 978-988.	0.3	766
2	Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO Instrument. Value in Health, 2011, 14, 967-977.	0.3	747
3	Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review. American Journal of Kidney Diseases, 2010, 55, 519-534.	1.9	60
4	Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. Journal of Dermatological Treatment, 2013, 24, 356-360.	2.2	58
5	Assessment of Patient-Reported Outcome Instruments to Assess Chronic Low Back Pain. Pain Medicine, 2017, 18, 1098-1110.	1.9	43
6	Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. Journal of Dermatological Treatment, 2013, 24, 255-260.	2.2	35
7	Measuring satisfaction with migraine treatment: Expectations, importance, outcomes, and global ratings. Clinical Therapeutics, 2003, 25, 2920-2935.	2.5	29
8	Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. Journal of Dermatological Treatment, 2016, 27, 224-227.	2.2	24
9	Content validation of two SF-36 subscales for use in type 2 diabetes and non-dialysis chronic kidney disease-related anemia. Quality of Life Research, 2011, 20, 889-901.	3.1	18
10	Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory. Quality of Life Research, 2014, 23, 897-906.	3.1	16
11	The experience of pain and redness in patients with moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 2015, 26, 401-405.	2.2	15
12	Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: part 1â€"the Patient Assessment for Low Back Pain - Symptoms (PAL-S). Pain, 2018, 159, 1045-1055.	4.2	13
13	Development of the Asthma Treatment Satisfaction Measure. Current Medical Research and Opinion, 2009, 25, 2495-2506.	1.9	12
14	Understanding polycystic ovary syndrome from the patient perspective: a concept elicitation patient interview study. Health and Quality of Life Outcomes, 2017, 15, 162.	2.4	11
15	Further Validation of an Individualized Migraine Treatment Satisfaction Measure. Value in Health, 2008, 11, 904-912.	0.3	9
16	Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: part 2â€"The Patient Assessment for Low Back Painâ€"Impacts (PAL-I). Pain, 2018, 159, 2066-2075.	4.2	7
17	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. American Journal of Clinical Dermatology, 2019, 20, 699-709.	6.7	5
18	Pain assessment for chronic lower back pain: performance of the PAL-S and PAL-I patient-reported measures for symptoms and impacts. Current Medical Research and Opinion, 2020, 36, 853-863.	1.9	3